FOR CAMBRIDGE-BASED Biogen, it’s been the best of times and the worst of times. The biotech powerhouse saw its Alzheimer’s drug Aduhelm approved in June by the Food and Drug […]
Biogen
Posted inHealth Care
FDA’s controversial approval of Alzheimer’s drug draws calls for reform
WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the […]
Posted inHealth Care
Insurers put squeeze on Biogen Alzheimer’s drug
CALL IT THE first big shot across Biogen’s bow in what may become a multi-billion-dollar war in which the hopes of millions for a way to hold back the ravages […]